

## **Q2 2018 – Conference Call Note**

Dr. Rudolf Staudigl (CEO), Dr. Tobias Ohler (CFO) July 26, 2018

### **Disclaimer**

The information contained in this presentation is for background purposes only and is subject to amendment, revision and updating. Certain statements and information contained in this presentation may relate to future expectations and other forward-looking statements that are based on management's current views and assumptions and involve known and unknown risks and uncertainties. In addition to statements which are forward-looking by reason of context, including without limitation, statements referring to risk limitations, operational profitability, financial strength, performance targets, profitable growth opportunities, and risk adequate pricing, other words such as "may, will, should, expects, plans, intends, anticipates, believes, estimates, predicts, or continue", "potential, future, or further", and similar expressions identify forward-looking statements. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions which could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These include, among other factors, changing business or other market conditions and the prospects for growth anticipated by the Company's management. These and other factors could adversely affect the outcome and financial effects of the plans and events described herein. Statements contained in this presentation regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. The Company does not undertake any obligation to update or revise any statements contained in this presentation, whether as a result of new information, future events or otherwise. In particular, you should not place undue reliance on forward-looking statements, which speak only as of the date of this presentation.

Cover - In April, WACKER acquired a production plant in the Netherlands for pharmaceutical proteins, live microbial products and vaccines. The acquisition is a key step for WACKER's ongoing expansion in the high-growth biopharmaceuticals market.

# **Highlights Q2 2018 Strong Performance in SILICONES**

#### **Solid Performance in Q2 2018**

	Sales of €1.3bn (+9% yoy, +9% qoq)
Financials	<b>EBITDA</b> at €261m (+3% yoy, +2% qoq)
	Net financial debt at €640m after €224m dividend payout in Q2
	Price and product mix drive SILICONES growth
Operations	FX headwinds and higher raw material prices yoy
	High utilization across all segments, POLYSILICON USA ramping

## **Profit & Loss Statement Strong Operations and Supportive Pricing Drive Results**

### **WACKER P&L Q2 2018 (€m)**


WACKER I WE WE ZOTO		
€m	Q2 2017	Q2 2018
Sales	1,218.3	1,329.9
Gross profit from sales	237.8	251.5
Gross profit margin (in %)	19.5%	18.9%
S,G&A and R&D Other operating income Other operating expenses	-149.0 19.9 -13.6	-156.7 24.7 -18.4
Operating result	95.1	101.1
Result from investments in joint ventures and associates	4.9	23.9
EBIT	101.9	125.0
Interest result Other financial result	-8.1 -18.0	-4.1 -12.7
Profit before tax	75.8	108.2
Income taxes	-15.3	-24.7
Income from continuing operations	60.5	83.5
Income from discontinued operations	0.0	0.0
Net income for the period	60.5	83.5
<b>EPS from continuing operations</b> (in €)	1.17	1.59
EBITDA	253.4	260.5
Depreciation/amortization	151.5	135.5
EBIT	101.9	125.0

#### **Comments**

- Sales +9.2% yoy:Volume/Mix +7.0%, Price +4.9%, FX -2.7%
- Gross profit increased by 5.8% yoy following higher prices, mix effects, efficiency gains and lower depreciation
- Result from investments in joint ventures and associates benefits from at-equity contribution from Siltronic
- Tax rate of 23.7% (6M 2017: 26.9%)
- Depreciation at €136m, -10.6% yoy
- ▶ EPS cont. operations at €1.59, +36% yoy

# **Balance Sheet Composition No Major Change in H1 2018**

### **Balance sheet (%)**



#### Characteristics 06/30/18

- Non current assets: €4,788m
- Securities, cash and cash equivalents: €389m
- Provisions for pensions: €1,721m (Mar 31, 2018: €1,692m)
  - Discount rate in Germany at 1.99% (Dec 31, 2017: 2.09%)
  - DTA\* relating to pensions about €341m
- Equity: €3,066m (Mar 31, 2018: €3,162m)

\* Deferred tax asset


## SILICONES Volume, Mix and Price Drive Strong Performance



## EBITDA (€m) / margin



## CapEx (€m)



### **Highlights Q2**

- Market tightness continues
- Operating at capacity limits
- Pricing and product mix drive sales and EBITDA growth

- Now targeting FY Sales of €2.5bn with an EBITDA around €600m
- Supportive pricing, high plant loading and good cost performance

# POLYMERS Volume and Price Gains Offset by Higher Raw Materials



### EBITDA (€m) / margin



## CapEx (€m)




#### **Highlights Q2**

- Positive pricing and volume effects did not compensate for higher raw materials
- VAM turnaround completed in May; impacts
   Q2 with about €15m

- Mid-single-digit % sales growth
- Volume growth and better pricing expected;
   headwinds from raws continuing
- H2 EBITDA performance similar to H1, resulting in FY at about €150m


# **BIOSOLUTIONS Good Performance in Pharma/Agro Reduced by Integration**



### EBITDA (€m) / margin



## CapEx (€m)




### **Highlights Q2**

- Strong performance in pharma/agro
- Gumbase with higher raw materials
- ▶ Integration efforts from recent M&A

- Mid-single-digit % sales growth
- ► EBITDA at about €25m following raw material increases, integration and ramp costs

## **POLYSILICON**


## Tennessee Ramp and Temporary Market Slowdown in Q2



### EBITDA (€m) / margin



## CapEx (€m)




### **Highlights Q2**

- WACKER German plants at full capacity,
   US ramp on track
- Slow China demand triggers inventory clearing in the solar value chain
- No insurance compensation for business interruption accounted for yet

- Sales low-double-digits % down
- ▶ EBITDA around 10% below 2017

## **Net Financial Debt Dividend Payment in Q2**

## Net Financial Debt Bridge per 06/30/2018 (€m)



Net financial debt as of Dec. 31, 2017

Cash flow from operating activities (gross cash flow)

long-term investing activities before securities \*

Cash flow from Dividend Wacker Exchange-rate effects and other Chemie AG effects


Net financial debt as of June 30, 2018

\*) includes financial investments

# **Guidance FY 2018 Outlook Confirmed, Updates for CapEx and Net Debt**

€m	2017	Outlook 2018
Sales	4,924	Low-single-digit % increase
EBITDA	1,014	Mid-single-digit % increase
EBITDA margin (%)	20.6	Slightly higher than a year ago
Net cash flow	358	Clearly positive, substantially below last year's figure
CapEx	327	<b>Around 450</b> (was: around 470)
Net financial debt	454	About 500 (was: on par with last year)
Income from continuing operations	250	Substantially higher than last year
Depreciation	590	Around 550
ROCE (%)	7.5	Substantially above the prior-year level
Tax Rate (cont. operations) (%)	25.3	Stable





Q2 2018 - Conference Call: Q&A Session

Dr. Rudolf Staudigl (CEO), Dr. Tobias Ohler (CFO) July 26, 2018

## Q2 2018 Results Sales and EBITDA Breakdown

**Q2 2018 Sales Q2 2018 EBITDA** 3% 3% 15% 18% Total: Total: 12% 49% €1.3bn €261m 2% 26% 68% 4%

SILICONES BIOSOLUTIONS POLYMERS POLYSILICON OTHERS / CONSOLID.

## Q2 2018 Results P&L

in€m	Q2 2018	Q2 2017	% YoY	Q1 2018	% QoQ
Sales	1,329.9	1,218.3	+9.2%	1,217.6	+9.2%
EBITDA	260.5	253.4	+2.8%	254.5	+2.4%
EBITDA margin	19.6%	20.8%	-	20.9%	-
EBIT	125.0	101.9	+22.7%	121.7	+2.7%
EBIT margin	9.4%	8.4%	-	10.0%	-
Net income for the period	83.5	60.5	+38.0%	79.1	+5.6%
EPS (cont. operations) in €	1.59	1.17	+35.7%	1.52	+4.6%

## Q2 2018 Results Breakdown by Business

	SALES					EBITDA				
In €m / %	Q2 2018	Q2 2017	% YoY	Q1 2018	% QoQ	Q2 2018	Q2 2017	% YoY	Q1 2018	% QoQ
CHEMICALS	1,054	935	+13%	962	+10%	215	182	+18%	201	+7%
SILICONES	654	549	+19%	606	+8%	177	111	+59%	149	+19%
POLYMERS	343	335	+2%	302	+14%	33	62	-48%	42	-22%
BIOSOLUTIONS	57	51	+11%	54	+5%	5	9	-41%	10	-47%
POLYSILICON	242	247	-2%	219	+10%	39	71	-45%	48	-19%
Others	39	40	-2%	43	-8%	7	-1	-	7	0%
Consolidation	-6	-4	-	-6	-	-1	1	-	-1	-
WACKER Group	1,330	1,218	+9%	1,218	+9%	261	253	+3%	255	+2%


## **Further PV Growth Expected in 2018**

Country	2014	2015	2016	2017	2018e
France	0.9	0.9	0.6	0.9	1.2 - 1.4
Germany	1.9	1.5	1.5	1.8	2.0 - 2.4
Europe other	4.6	6.2	4.3	~ 4.1	7.2 – 9.0
Europe total	7.4	8.6	6.4	~ 6.8	10.4 – 12.8
Australia	1.0	0.9	0.8	1.3	2.7 - 3.0
China*	13.2	16.5	32.5	52.8	40.0 - 45.0
India	1.0	2.1	4.3	9.6	10.0 – 11.0
Japan	9.3	10.8	8.4	~ 7.4	7.0 - 8.0
South Korea	0.9	1.0	0.9	1.2	1.5 – 1.7
USA	6.2	7.3	14.8	10.6	10.0 –13.0
Rest of World	5.1	9.0	9.8	~ 10.5	18.0 - 20.0
Total	44 GW	56 GW	78 GW	~ 100 GW	100 – 115 GW


Sources: SPE, IHS, industry announcements, WACKER estimates; \*China official data adjusted for installed/not connected capacity




## **Raw Material Prices With Volatile Development**









Source: ICIS, MeOH Contract, FOB RDM

Source: ICIS, VAM Contract FD NWE

## **WACKER:** Issuer, Contact and Additional Information

#### **Issuer and Contact**

#### INVESTOR RELATIONS CONTACTS

#### Joerg Hoffmann, CFA

Tel. +49 89 6279 1633 joerg.hoffmann@wacker.com

#### **Scott McCollister**

Tel. +49 89 6279 1560 scott.mccollister@wacker.com

#### **Monika Stadler**

Tel. +49 89 6279 2769 monika.stadler.IR@wacker.com

Wacker Chemie AG Hanns-Seidel-Platz 4 **D-81737 Munich** 

#### **Financial Calendar**

#### 10/25/18

Q3 Results 2018

#### **Additional Information**





#### ISIN

DE000WCH8881

#### WKN

WCH888

#### **Deutsche Börse** WCH

#### **Publications**





